On November 13, 2020 Olema Oncology, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, reported a clinical trial agreement to evaluate OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in combination with palbociclib (IBRANCE) in patients with recurrent, locally advanced or metastatic estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer (Press release, Olema Pharmaceuticals, NOV 13, 2020, View Source [SID1234570942]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This agreement with Pfizer represents continued momentum toward our goal of advancing the clinical development of OP-1250," said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. "We look forward to learning more about the potential of OP-1250 in combination with palbociclib in patients living with breast cancer."
Under the terms of the non-exclusive agreement, Olema is responsible for conducting the trial and Pfizer is responsible for supplying its study drug.